IMRX vs PH · $124.2M cap vs P/E 28, rev $19.85B
Immuneering Corp (IMRX) versus Parker-Hannifin Corporation (PH) — a side-by-side from cached financials, not a winner call.
Immuneering Corp (IMRX) is a biotechnology company listed on US.
Parker-Hannifin Corporation (PH) is a specialty industrial machinery company listed on US.
Latest reported IMRX revenue for 2023-12-31 was $0. Net income was -$53.5M. Revenue was down 100.0% from 2022-12-31 to 2023-12-31. IMRX currently screens at market cap $124.2M.
Latest reported PH revenue for 2025-06-30 was $19.85B. Net income was $3.53B. PH currently screens at market cap $91.89B and trailing P/E 27.7.
IMRX currently screens at market cap $124.2M. PH currently screens at market cap $91.89B and trailing P/E 27.7.
Not investment advice. Open the IMRX and PH stock pages for the full models.
Not investment advice.